Zobrazeno 1 - 10
of 325
pro vyhledávání: '"Blair Jarvis"'
Autor:
David R. Nelson, Stefan Zeuzem, Pietro Andreone, Peter Ferenci, Robert Herring, Donald M. Jensen, Patrick Marcellin, Paul J. Pockros, Maribel Rodríguez-Torres, Lorenzo Rossaro, Vinod K. Rustgi, Thomas Sepe, Mark Sulkowski, Isaac R. Thomason, Eric M. Yoshida, Anna Chan, George Hill
Publikováno v:
Annals of Hepatology, Vol 11, Iss 1, Pp 15-31 (2012)
Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment re
Externí odkaz:
https://doaj.org/article/2d5eecb9e39e415a9b83005ddc1364ab
Autor:
Blair Jarvis
Publikováno v:
The International Encyclopedia of Communication Research Methods. :1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::057e1d2d8f76907147cb1729897e21f7
https://doi.org/10.1002/9781118901731.iecrm0147
https://doi.org/10.1002/9781118901731.iecrm0147
Autor:
Kipling D. Williams, Blair Jarvis
Publikováno v:
Behavior Research Methods. 38:174-180
Since the mid-1990s, research on interpersonal acceptance and exclusion has proliferated, and several paradigms have evolved that vary in their efficiency, context specificity, and strength. This article describes one such paradigm, Cyberball, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605a8e3fe6d333171aaa27d1aaad094f
https://doi.org/10.3758/bf03192765
https://doi.org/10.3758/bf03192765
Publikováno v:
Drugs. 64:969-982
▴ Micafungin, an echinocandin antifungal agent with a novel mechanism of action, inhibits β-(l,3)-D-glucan synthase interfering with fungal cell wall synthesis. It shows excellent antifungal activity against a broad range of Candida spp., includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12af962a9468e7d8aeb2240cc32a898f
https://doi.org/10.2165/00003495-200464090-00004
https://doi.org/10.2165/00003495-200464090-00004
Autor:
Blair Jarvis, David P. Figgitt
Publikováno v:
Drugs. 63:207-213
One month after the last dose (i.e. at month 7), geometric mean titres (GMTs) of antibodies directed against hepatitis A virus (anti-HAV) were generally greater in participants (aged 12-15 years) receiving combined two-dose (0 and 6 months) hepatitis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4605a7a0d8341ff1a3400850c136aee
https://doi.org/10.2165/00003495-200363020-00006
https://doi.org/10.2165/00003495-200363020-00006
Autor:
Keri Wellington, Blair Jarvis
Publikováno v:
Drugs. 62:817-840
Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a nonsteroid, has anti-inflammatory activity, and has demonstrated efficacy in reducing symptoms of atopic dermatitis in adult and paediatric patients when applied topically. Compared with vehic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ecb8268e47072fbf9a386b0931a396e
https://doi.org/10.2165/00003495-200262050-00007
https://doi.org/10.2165/00003495-200262050-00007
Autor:
Keri Wellington, Blair Jarvis
Publikováno v:
CNS Drugs. 16:715-720
Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes. Earlier clinical trials demonstrated that rizatriptan 5 or 10mg is more effective than placebo at providing pain relief an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7e74d7ebc45d24e56fb85bd1f5d0b5a
https://doi.org/10.2165/00023210-200216100-00005
https://doi.org/10.2165/00023210-200216100-00005
Autor:
Stephanie E Easthope, Blair Jarvis
Publikováno v:
Drugs. 62:1253-1287
Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (ATi) receptor prevents bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44c4525a9c89bbeb31a3152a6f46ea4
https://doi.org/10.2165/00003495-200262080-00016
https://doi.org/10.2165/00003495-200262080-00016
Autor:
Blair Jarvis, Gillian M. Keating
Publikováno v:
American Journal of Cancer. 1:351-371
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cebf87057f3d0222b4ab1249eb36ac3f
https://doi.org/10.2165/00024669-200201050-00007
https://doi.org/10.2165/00024669-200201050-00007
Publikováno v:
Drugs. 62:2075-2085
▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively metabolised and has a low propensity for drug interactions. ▴ In well designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae672843ccfa6c9abf072cb67d99c88
https://doi.org/10.2165/00003495-200262140-00008
https://doi.org/10.2165/00003495-200262140-00008